Related Experiment Video
Updated: Jul 8, 2026
08:47
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Severe acute hyperammonemia after brief exposure to valproate
Aubrey L Eubanks1, Betzabel Aguirre, James A Bourgeois
1Dept. of Psychiatry and Behavioral Sciences, Univ. of California, Davis Medical Center, 2230 Stockton Blvd., Sacramento CA 95817, USA.
Psychosomatics
|January 24, 2008
Summary
Acute hyperammonemia, a serious condition, can occur when valproate is added to psychotropic medications. Prompt intervention and supportive care effectively resolved the patient's delirium.
Area of Science:
- Neuroscience
- Clinical Pharmacology
- Toxicology
Background:
- Valproate is a widely used antiepileptic and mood-stabilizing drug.
- Psychotropic medications are frequently prescribed for various mental health conditions.
- Drug interactions, especially in patients on polypharmacy, can lead to adverse events.
Purpose of the Study:
- To report a case of acute hyperammonemia secondary to valproate addition in a patient on multiple psychotropic medications.
- To highlight the clinical presentation of drug-induced hyperammonemia.
- To emphasize the importance of prompt recognition and management of this condition.
Main Methods:
- Case report detailing a patient's clinical course.
- Review of medication history, focusing on the addition of valproate.
- Monitoring of ammonia levels and mental status.
- Description of interventions and patient's response.
Main Results:
- The patient developed acute mental-status changes, consistent with delirium, after initiating valproate.
- Elevated ammonia levels confirmed hyperammonemia.
- Discontinuation of valproate and supportive care led to rapid resolution of delirium.
Conclusions:
- Valproate can precipitate acute hyperammonemia, even in patients without pre-existing liver disease.
- Mental-status changes in patients on valproate and other psychotropic medications should prompt evaluation for hyperammonemia.
- Early diagnosis and management are crucial for favorable outcomes.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:14Prevention of Further Absorption of Poison
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...